Regeneron Pharmaceuticals is buying 23andMe for $256 million, ... Its co-founder and CEO Anne Wojcicki also resigned from the top post, but remained as a board member.

-Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning bid of $256 million, a company spokesperson told Reuters on Monday.

Regeneron wins bid to buy 23andMe out of bankruptcy. Ned Pagliarulo . Mon, May 19, 2025, 4:00 AM 3 min read. In This Article: REGN . This story was originally published on BioPharma Dive.

Regeneron Pharmaceuticals, a biotechnology company with a long history of large-scale genetics research, plans to buy DNA testing firm 23andMe out of bankruptcy, announcing Monday it was named the ...

Regeneron Pharmaceuticals has announced that it will be acquiring human genetics and biotechnology company 23andMe for $256m. ... 23andMe’s interim chief executive officer, Joe Selsavage, added that ...

WHY IT'S IMPORTANT. Co-founder Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls topped Regeneron's offer for the DNA-testing company in a ...

A court has approved the $305m sale of 23andMe’s assets to a nonprofit led by former 23andMe CEO Anne Wojcicki.

Co-founder Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls topped Regeneron's offer for the DNA-testing company in a bankruptcy auction.

States with privacy objections to the sale have until July 7 to reach a stay to appeal the case. TTAM, a nonprofit started by ...